Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132573 · ClinicalTrials.gov registry record · Phase 1
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
A Phase 1 study of Recurrent Adult Acute Lymphoblastic Leukemia and Untreated Adult Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT01132573: Completed Phase 1 study of Recurrent Adult Acute Lymphoblastic Leukemia and Untreated Adult Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).
NCT01132573 is a Phase 1 study of Recurrent Adult Acute Lymphoblastic Leukemia and Untreated Adult Acute Lymphoblastic Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants, below the 67-participant average among 8 other Recurrent Adult Acute Lymphoblastic Leukemia trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01132573, a Phase 1 study of Recurrent Adult Acute Lymphoblastic Leukemia and Untreated Adult Acute Lymphoblastic Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/biphenotypic leukemia. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving entinostat with clofarabine may kill more cancer cells.
Primary Outcome
The frequency of the observed toxicities will be tabulated by type and grade.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG clofarabine
- DRUG entinostat
Study Locations (4)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- University of Colorado - Denver
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-04 |
| Phase | Phase 1 |
What the finished NCT01132573 record still lists
NCT01132573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 67-participant average among 8 other Recurrent Adult Acute Lymphoblastic Leukemia trials with a reported enrollment target (60% lower).
The record links to 4 conditions, with Recurrent Adult Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01132573 reports a single indexed study location in Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT01132573 about?
NCT01132573 is a clinical study titled "Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia". This phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or bilineage/biphenotypic leukemia. Entinostat may stop the growth of cancer cells by...
What is the current status of trial NCT01132573?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-04.
What conditions does trial NCT01132573 study?
This clinical trial studies the following conditions: Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT01132573?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), clofarabine (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT01132573?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01132573 being conducted?
This trial has 4 study locations across Colorado, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01132573's enrollment target sits among peer trials
27 8th of 8 higher than 1 of 8 other Recurrent Adult Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
COMPLETED · Phase 1
-
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
COMPLETED · Phase 1
-
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia